Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective

Overlapping eligibility to different biologics for severe asthma is still challenging, especially when addressing the same target. We aimed to characterize severe eosinophilic asthma patients according to their maintained or reduced response to mepolizumab over time and to explore baseline variables...

Descripción completa

Detalles Bibliográficos
Autores principales: Caminati, Marco, Marcon, Alessandro, Guarnieri, Gabriella, Miotti, Jessica, Bagnasco, Diego, Carpagnano, Giovanna Elisiana, Pelaia, Girolamo, Vaia, Rachele, Maule, Matteo, Vianello, Andrea, Senna, Gianenrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002580/
https://www.ncbi.nlm.nih.gov/pubmed/36902623
http://dx.doi.org/10.3390/jcm12051836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002580/
https://www.ncbi.nlm.nih.gov/pubmed/36902623
http://dx.doi.org/10.3390/jcm12051836

Ejemplares similares